×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
INSM – insmed incorporated (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
INSM
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/24
09:51 am
insm
Insmed Incorporated (INSM) PT Lifted to $230 as Guggenheim Updates Biotech Earnings Models [Yahoo! Finance]
Low
Report
Insmed Incorporated (INSM) PT Lifted to $230 as Guggenheim Updates Biotech Earnings Models [Yahoo! Finance]
4/24
09:33 am
insm
How The Insmed (INSM) Investment Story Is Shifting On Brinsupri And ENCORE Developments [Yahoo! Finance]
Medium
Report
How The Insmed (INSM) Investment Story Is Shifting On Brinsupri And ENCORE Developments [Yahoo! Finance]
4/23
07:00 am
insm
Insmed to Host First-Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026
Low
Report
Insmed to Host First-Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026
4/17
02:18 pm
insm
Insmed (INSM) had its "buy" rating reaffirmed by Roth Mkm. They now have a $212.00 price target on the stock.
Low
Report
Insmed (INSM) had its "buy" rating reaffirmed by Roth Mkm. They now have a $212.00 price target on the stock.
4/16
07:15 am
insm
Insmed (INSM) had its "buy" rating reaffirmed by Guggenheim.
Low
Report
Insmed (INSM) had its "buy" rating reaffirmed by Guggenheim.
4/14
08:57 am
insm
Insmed (INSM) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
Low
Report
Insmed (INSM) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
4/11
05:32 am
insm
Insmed (INSM) was upgraded by Raymond James Financial, Inc. to "moderate buy".
Low
Report
Insmed (INSM) was upgraded by Raymond James Financial, Inc. to "moderate buy".
4/10
09:00 am
insm
Insmed (INSM) is now covered by Raymond James Financial, Inc.. They set an "outperform" rating and a $200.00 price target on the stock.
Medium
Report
Insmed (INSM) is now covered by Raymond James Financial, Inc.. They set an "outperform" rating and a $200.00 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/17
04:43 pm
insm
Form 4 INSMED Inc For: Apr 16 Filed by: Lewis William
Low
Report
Form 4 INSMED Inc For: Apr 16 Filed by: Lewis William
4/16
04:17 pm
insm
Form 144 INSMED Inc Filed by: Lewis William
Low
Report
Form 144 INSMED Inc Filed by: Lewis William
4/8
04:41 pm
insm
Form 4 INSMED Inc For: Apr 06 Filed by: Lewis William
Low
Report
Form 4 INSMED Inc For: Apr 06 Filed by: Lewis William
4/6
04:43 pm
insm
Form 144 INSMED Inc Filed by: Lewis William
Low
Report
Form 144 INSMED Inc Filed by: Lewis William
4/3
04:08 pm
insm
Form 4 INSMED Inc For: Apr 01 Filed by: Adsett Roger
Low
Report
Form 4 INSMED Inc For: Apr 01 Filed by: Adsett Roger
4/1
05:11 pm
insm
Form 144 INSMED Inc Filed by: Adsett Roger
Low
Report
Form 144 INSMED Inc Filed by: Adsett Roger
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/3
Insmed Announces Positive Top-Line Results from Phase 2 WILLOW Study of INS1007 in Patients with Non-Cystic Fibrosis Bronchiectasis
40.6%
2/4 Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at Goldman Sachs Group Inc from $33.00 to $46.00. They now have a "buy" rating on the stock. 12.6%
3/17 Insmed Incorporated (NASDAQ: INSM) had its price target lowered by analysts at Stifel Nicolaus from $55.00 to $45.00. They now have a "buy" rating on the stock. 12.6%
4/30 Insmed Reports First Quarter 2020 Financial Results and Provides Business Update 8.0%
10/11 Insmed Incorporated (NASDAQ: INSM) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 7.9%
4/2 Insmed Appoints Carol A. Schafer to its Board of Directors 7.1%
10/30 Form 10-Q INSMED Inc For: Sep 30 6.7%
4/20 Insmed to Host First Quarter 2020 Financial Results Conference Call on Thursday, April 30, 2020 6.5%
1/7 Form 4 INSMED Inc For: Jan 03 Filed by: SORIANO JOHN 6.1%
6/12 Form 3 INSMED Inc For: Jun 03 Filed by: GOLL JOHN 5.7%
2/4 Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at Goldman Sachs Group Inc from $33.00 to $46.00. They now have a "buy" rating on the stock. 12.6%
3/17 Insmed Incorporated (NASDAQ: INSM) had its price target lowered by analysts at Stifel Nicolaus from $55.00 to $45.00. They now have a "buy" rating on the stock. 12.6%
4/30 Insmed Reports First Quarter 2020 Financial Results and Provides Business Update 8.0%
10/11 Insmed Incorporated (NASDAQ: INSM) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 7.9%
4/2 Insmed Appoints Carol A. Schafer to its Board of Directors 7.1%
10/30 Form 10-Q INSMED Inc For: Sep 30 6.7%
4/20 Insmed to Host First Quarter 2020 Financial Results Conference Call on Thursday, April 30, 2020 6.5%
1/7 Form 4 INSMED Inc For: Jan 03 Filed by: SORIANO JOHN 6.1%
6/12 Form 3 INSMED Inc For: Jun 03 Filed by: GOLL JOHN 5.7%
TOP News Decliners
2/25
Q4/2019 12/31/2019 EPS -0.590 ZacksConsensus -0.590 ActVsEst 0.000 - In-Line
-16.4%
5/7 Q1/2019 3/31/2019 EPS -0.960 ZacksConsensus -0.940 ActVsEst (0.020) - Miss -13.0%
8/1 Q2/2019 6/30/2019 EPS -0.810 ZacksConsensus -0.850 ActVsEst 0.040 - Beat -12.3%
2/26 Galapagos Ratings Downgrade, And Other News: The Good, Bad And Ugly Of Biopharma [Seeking Alpha] -8.1%
3/31 Form DEFA14A INSMED Inc -6.6%
8/2 Insmed, Inc. (INSM) CEO Will Lewis on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -6.1%
5/20 New Phase 3 Data Show Sustainability and Durability of Culture Conversion with ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with Refractory MAC Lung Disease -5.9%
3/7 Insmed Incorporated (NASDAQ: INSM) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -5.9%
3/5 Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) -5.7%
1/16 Insmed Incorporated (NASDAQ: INSM) had its "buy" rating re-affirmed by analysts at JMP Securities. They now have a $40.00 price target on the stock. -5.0%
5/7 Q1/2019 3/31/2019 EPS -0.960 ZacksConsensus -0.940 ActVsEst (0.020) - Miss -13.0%
8/1 Q2/2019 6/30/2019 EPS -0.810 ZacksConsensus -0.850 ActVsEst 0.040 - Beat -12.3%
2/26 Galapagos Ratings Downgrade, And Other News: The Good, Bad And Ugly Of Biopharma [Seeking Alpha] -8.1%
3/31 Form DEFA14A INSMED Inc -6.6%
8/2 Insmed, Inc. (INSM) CEO Will Lewis on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -6.1%
5/20 New Phase 3 Data Show Sustainability and Durability of Culture Conversion with ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with Refractory MAC Lung Disease -5.9%
3/7 Insmed Incorporated (NASDAQ: INSM) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -5.9%
3/5 Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) -5.7%
1/16 Insmed Incorporated (NASDAQ: INSM) had its "buy" rating re-affirmed by analysts at JMP Securities. They now have a $40.00 price target on the stock. -5.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: